Ikarian Capital’s Novavax NVAX Stock Holding History

Ikarian Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300,000	Closed	-$2.41M	–	202
2024 Q4	$2.41M	Buy	+300,000	New	+$2.89M	0.33%	73
2024 Q1	–	Sell	-713,200	Closed	-$3.42M	–	169
2023 Q4	$3.42M	Buy	713,200 +706,068	+9,900%	+$4.32M	0.32%	72
2023 Q3	$5.16M	Sell	7,132 -392,868	-98%	-$3.14M	0.62%	49
2023 Q2	$2.97M	Buy	+400,000	New	+$3.15M	0.47%	52
2021 Q4	–	Sell	-70,000	Closed	-$14.5M	–	222
2021 Q3	$14.5M	Buy	+70,000	New	+$15.4M	1.02%	22
2021 Q2	–	Sell	-70,000	Closed	-$12.7M	–	261
2021 Q1	$12.7M	Buy	+70,000	New	+$13.9M	0.43%	53

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's NVAX Position: Q2 2022 in Review

Ikarian Capital sold out of Novavax (NVAX) in Q2 2022, closing a stake of 1,362 shares — an estimated $100K sold.

Ikarian Capital first reported a position in NVAX in Q4 2019 and held it in 8 quarters. The position peaked at $559K in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Ikarian Capital reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 1,362 Novavax shares in Q2 2022, an estimated $100K.
Ikarian Capital first reported a position in Novavax in Q4 2019 and held it in 8 quarters.
Ikarian Capital's Novavax position peaked at $559K in Q2 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.